EORTC collaborates with IDDI on ground-breaking statistical method for individualisation of therapy
The treatment of patients in clinical practice relies on the [...]
EORTC – STOA Workshop INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE
Developing novel approach to deliver better precision medicines in Europe [...]
New trial in Glioblastoma – step forward in the battle against an aggressive and incurable disease
Glioblastoma is a fast-growing malignant brain tumour that develops from [...]
Conclusions of IBCD 2018, the regulatory science meeting for precision medicine
The 2018 edition of the Innovation and Biomarkers in Cancer [...]
Major EORTC trial presented at San Antonio Breast Cancer Symposium: 10-year follow-up of AMAROS shows benefits for post-operative radiotherapy to the axilla in patients with a tumour-positive sentinel node GalleryMajor EORTC trial presented at San Antonio Breast Cancer Symposium: 10-year follow-up of AMAROS shows benefits for post-operative radiotherapy to the axilla in patients with a tumour-positive sentinel node
Major EORTC trial presented at San Antonio Breast Cancer Symposium: 10-year follow-up of AMAROS shows benefits for post-operative radiotherapy to the axilla in patients with a tumour-positive sentinel node
Results from a 10-year follow of patients in the EORTC [...]
The EORTC Brain Tumor Group and Protagen AG announce their collaboration to investigate the immuno-competence of long-term Glioblastoma survivors
Zurich, Switzerland and Dortmund, Germany – 4 December 2018 – [...]
EORTC at ISOQOL Annual Conference: President’s Award and 12 EORTC abstracts
The International Society for Quality of Life Research (ISOQOL) is [...]
Diverging EU Health Regulations: The urgent need for coordination and convergence
Clinical research is bound to very complex legal framework. The [...]
The final analysis of SPLENDOUR trial did not show improvement in overall survival in advanced Non-Small Lung Cancer
Results of the EORTC- ETOP SPLENDOUR trial will be presented [...]
EORTC abstracts at ESMO 2018
Results from a number of EORTC trials will be presented [...]
